National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 40 of 66
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
NCT00387465
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
NCT00305734
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
NCT00383474
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
NCT00381550
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00387335
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00387751
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
NCT00381797
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
NCT00368927
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00368992
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
NCT00313586
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
NCT00369590
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00365391
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
NCT00258349
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
NCT00365274
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
NCT00321685
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00376688
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
NCT00923169
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
NCT00904579
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
NCT00362882
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
NCT00348699
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00669019
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
NCT00368875
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium
NCT00559767
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
NCT00334789
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
NCT00314119
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
NCT00360776
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
NCT00351975
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
NCT00352365
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
NCT00357318
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
NCT00454571
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
NCT00369174
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
NCT00363272
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00293345
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
NCT00357708
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
NCT00365053
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
NCT00330421
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00262925
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT00369551
AFP464 in Treating Patients With Advanced Solid Tumors
NCT00369200
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
NCT00363779
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
NCT00363883
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
NCT01445080
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495
LMB-2 to Treat Hairy Cell Leukemia
NCT00321555
CDDO to Treat Solid Tumors and Lymphomas
NCT00322140
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
NCT00321581
PXD101 in Treating Patients With Acute Myeloid Leukemia
NCT00357032
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
NCT00356889
Belinostat in Treating Patients With Myelodysplastic Syndromes
NCT00357162
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
NCT00321594
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.